Report Publication Announcement • Feb 28, 2023
Report Publication Announcement
Open in ViewerOpens in native device viewer
Paris, France, Tuesday February 28, 2023, 5:45 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2023.
| Information | Date* |
|---|---|
| 2022 Full-Year Financial Update and Statements | March 24, 2023 |
| 2023 1Q Cash Position | April 20, 2023 |
| Annual General Meeting | May 16, 2023 |
| 2023 First-Half Financial Update and Statements | July 26, 2023 |
| 2023 3Q Cash Position | October 26, 2023 |
| 2023 4Q Cash Position | January 25, 2024 |
* This financial calendar is provided for information only and may be subject to changes. The Company's updated financial calendar is available on its corporate website.
Corporate Communications Director Clothilde Caillet [email protected]
Investor Relations Guillaume van Renterghem [email protected] +41 (0)76 735 01 31
Media Relations Jeanene Timberlake [email protected] +1 646-770-8858
Retail Investors James Palmer [email protected] +33 (0)7 60 92 77 74
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.